Cipla launches Yurpeak (Tirzepatide) in India for obesity and diabetes

Regulatory product approvalBusiness Updates View source PDF Explain this filing

CIPLA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.5%Reaction day

₹1490.00

prior close

₹1492.00

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)+0.5%+0.9% vs market

Pharmaceuticals peers, median of 156sector+0.6%+0.9% vs sector

On the reaction day the stock moved 0.9 pts more than Nifty 100 and 0.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

+0.4

15m

+0.5

30m

+0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.5+0.5+0.9+0.6+0.9

Next day

+1.8+1.2+0.6+1.0+0.7

+1.0+1.1-0.2+0.5+0.5

+0.7+0.5+0.2+0.1+0.5

+0.5+0.3+0.2-0.7+1.3

+0.5+0.2+0.2-0.6+1.1

+1.4+1.7-0.3+0.8+0.6

15d

+1.3+2.5-1.2+1.9-0.6

-1.7+0.4-2.1-1.9+0.1

-9.4+1.3-10.7-2.1-7.3

-10.9-6.4-4.5-6.4-4.5

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Cipla launched Yurpeak (Tirzepatide) in India on Dec 10, 2025 under a marketing and distribution deal with Eli Lilly. It is a once-weekly injectable for obesity and Type 2 Diabetes, available in six strengths from 2.5mg to 15mg via a KwikPen device, after DCGI approval. Cipla will distribute and promote the drug, while Lilly will manufacture and supply it, priced the same as Mounjaro. Cipla plans to expand access beyond metro cities.

Likely market impact

Broadens Cipla's portfolio in the fast-growing obesity and diabetes segments, potentially adding a high-growth revenue stream through its Lilly partnership.